Search Results

You are looking at 61 - 68 of 68 items for :

  • "temsirolimus" x
  • Refine by Access: All x
Clear All
Full access

Matthias Holdhoff, Maciej M. Mrugala, Christian Grommes, Thomas J. Kaley, Lode J. Swinnen, Carlos Perez-Heydrich, and Lakshmi Nayak

rituximab as second-line treatment of primary central nervous system lymphoma . Med Oncol 2015 ; 32 : 351 . 61. Korfel A , Schlegel U , Herrlinger U , . Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma . J Clin Oncol

Full access

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky, and Yoshiya Yamada

sunitinib, an oral anti-VEGF tyrosine kinase inhibitor, and temsirolimus, an intravenous mTOR inhibitor. The data are inconclusive and under active study, but antiangiogenic agents specifically may induce a window of vascular normalization that may have a

Full access

A. Dimitrios Colevas

phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma . Oral Oncol 2013 ; 49 : 461 – 467 . 56. Vermorken JB Psyrri A Mesia R . Impact of tumor

Full access

Kelly N. Fitzgerald and Chung-Han Lee

M , Tomczak P , Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 10.1056/NEJMoa066838 11. Motzer RJ , Mazumdar M , Bacik J , Survival and prognostic

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

advanced, HR-positive breast cancer with no prior endocrine therapy for advanced disease that randomized subjects to letrozole with or without the mTOR inhibitor temsirolimus has been reported. 64 In this study, PFS was not different between the treatment

Full access

Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland

anti-GRP MoAb], tipifarnib, gefitinib, dasatinib, everolimus, temsirolimus, ATRA); apoptotic pathway stimulators (oblimersen, obatoclax, AT-101); the HDAC inhibitor romidepsin; immunotargeted vaccines (BEC2); and immunotoxins (NCAM-ricin). 82 In

Full access

Matthew H. Kulke, Manisha H. Shah, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Lyska Emerson, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Whitney S. Goldner, Thorvardur R. Halfdanarson, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Jeffrey F. Moley, Gitonga Munene, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Christopher Wolfgang, James C. Yao, Jennifer Burns, and Deborah Freedman-Cass

risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors . Ann Oncol 2013 ; 24 : 2092 – 2097 . 72. Parithivel K Ramaiya N Jagannathan JP . Everolimusand temsirolimus

Full access

Matthew H. Kulke, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Michael A. Choti, Orlo H. Clark, Gerard M. Doherty, James Eason, Lyska Emerson, Paul F. Engstrom, Whitney S. Goldner, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Jeffrey F. Moley, Venu G. Pillarisetty, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Rebekah White, James C. Yao, Deborah A. Freedman-Cass, and Mary A. Dwyer

– 2012 . 64 Parithivel K Ramaiya N Jagannathan JP . Everolimus- and temsirolimus-associated enteritis: report of three cases . J Clin Oncol 2010 ; 29 : e404 – 406 . 65 Imhof A Brunner P Marincek N . Response, survival, and long